China Pharmaceutical Distribution Industry Report, 2019-2025
  • Jun.2019
  • Hard Copy
  • USD $2,900
  • Pages:135
  • Single User License
    (PDF Unprintable)       
  • USD $2,700
  • Code: ZLC082
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,100
  • Hard Copy + Single User License
  • USD $3,100
      

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017, of which drug retailing market size ranged at RMB437.7 billion in 2018, compared with RMB400.3 billion (up by 9% YoY) in 2017.

By product, western medicine is prevailing in Chinese pharmaceutical distribution market, sweeping 73.2% of total sales in 2018; by region, the east and the central south of China take larger shares, a combined 62.1% in 2018.

In China, a competitive pattern has taken shape that national drug distributors led by Sinopharm, China Resources Pharmaceutical Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group, and regional distribution companies such as Nanjing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun Pharmaceutical, Zhejiang Int’l Group, Realcan Pharmaceutical, Guangzhou Liuzhou Pharmaceutical and Luyan Phapma, compete with each other.

By the end of 2018, there had been 13,146 drug wholesalers competing fiercely in China, showing a low market concentration. In 2018, the top 100 by operating revenue commanded 70.7% of China’s pharmaceuticals market, and the first four leaders occupied 37.6%.

By the end of 2018, there had been 5,985 drugstore chains in possession of 463,200 retail stores in China, of which 242,560 were chain stores, taking up 52.4% of the total, up by 2 percentage points on an annualized basis; 88.3% of stores were directly run by retailers themselves; 72% were designated medical insurance stores. 

In China, leading drug retail chains include Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd., Dashenlin Pharmaceutical Group Co., Ltd., LBX Pharmacy, Yifeng Pharmacy, Sinopharm, China Nepstar Chain Drugstore, Gansu Zhongyou Health Medicine Co., Ltd., Suzhou Quanyi Health Drugstore Chain Co., Ltd., Chongqing Tong Jun Ge Co., Ltd. and Yunnan Jianzhijia Health Drugstore Chain Co., Ltd., among which Chongqing Tong Jun Ge Co., Ltd. has 10,575 drugstores, the most among all retail chains, and Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. boasts the largest number of direct-sale stores, numbering 5,758, all of which are directly operated by the company.

The immense potential of pharmaceutical distribution industry has attracted the inrush of capital in recent years, and mergers and acquisitions occurred frequently. Boosted by capital, drug circulation companies are gearing from traditional endogenous growth by adding more products, new stores and developing customers to extensive development by M&A and restructuring. The industry is becoming increasingly concentrated.

医药经销_副本.png

China Pharmaceutical Distribution Industry Report, 2019-2025 highlights the following:
20120114.gifChina pharmaceutical distribution industry (development environment, status quo, market size, market structure, competitive pattern and development trends);
20120114.gifChina drug retailing market (market size, gross margin and net margin, quantity, share of medical insurance designated stores, per customer transaction, and comparison of operating results between major drug retailers);
20120114.gif20 Chinese pharmaceutical distribution companies (operation, revenue structure, gross margin, development strategy, etc.).

1. Overview of Pharmaceutical Distribution Industry
1.1 Definition
1.2 Industry Chain
1.3 Strength and Weakness of Pharmaceutical Chain Enterprises
1.3.1 Strength of Pharmaceutical Chain Enterprises
1.3.2 Weakness of Pharmaceutical Chain Enterprises

2. Pharmaceutical Distribution Industry in China
2.1 Development Environment
2.1.1 Policy
2.1.2 Economy
2.1.3 Medical Institution
2.1.4 Health Expenditure
2.1.5 Aging
2.1.6 Per Capita Disposable Income
2.2 Status Quo
2.3 Market Size
2.4 Market Structure
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Pharmaceutical E-commerce Becomes an Important Model
2.6.2 Operating Efficiency and Service Functions Gets Improved Constantly
2.6.3 Capital Market Plays a Bigger Role in Integration of Enterprises
2.6.4 Pharmaceutical Supply-chain Management Services Are Upgraded Rapidly
2.6.5 Cross-border Integration of Pharmaceuticals and E-commerce Continues
2.6.6 Favorable Policies Make the Market More Concentrated 
2.6.7 Growing Trend towards Regionalization
2.6.8 Wholesale-retail Integration Spurs Industry Consolidation
2.6.9 Outflow of Prescriptions is a Boon for the Industry
2.6.10 Single Drugstores are Being Edged out by Drugstore Chains Which are Gaining Ground 

3 Chinese Drug Retail Market
3.1 Market Size
3.2 Gross Margin and Net Margin 
3.3 Quantity
3.3.1 Top100 Pharmacy Chains
3.3.2 Online Pharmacy
3.3.3 Independent Pharmacy
3.3.4 Shares of New Stores and Those Shut down 
3.4 Share of Medical Insurance Designated Stores 
3.5 Per Customer Transaction
3.6 Comparison of Operating Results between Major Drug Retailers

4. Major Enterprises
4.1 China National Accord Medicines Corporation Ltd.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Major Customers
4.1.5 Pharmaceutical Distribution Business
4.1.6 Development Strategy
4.2 Nanjing Pharmaceutical Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Development Strategy
4.3 Shanghai No.1 Pharmacy Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Development Strategy
4.4 China National Medicines Corporation Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Development Strategy
4.5 Huadong Medicine Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Customers
4.5.6 Development Strategy
4.6 Cachet Pharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Customers
4.6.6 Development Strategy
4.7 Jointown Pharmaceutical Group Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 Major Customers
4.7.6 Development Strategy
4.8 Realcan Pharmaceutical Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 Development Strategy
4.9 Shanghai Pharmaceuticals Holding Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 Development Strategy
4.10 Zhejiang Int'l Group Co., Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Development Strategy
4.11 Zhejiang Zhenyuan Share Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Development Strategy
4.12 China Meheco Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 Development Strategy
4.13 Charmacy Pharmaceutical Co., Ltd.
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Development Strategy
4.14 Luyan Pharma Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 Development Strategy
4.15 China Resources Pharmaceutical Group Limited
4.15.1 Profile
4.15.2 Operation
4.15.3 Revenue Structure
4.15.4 Gross Margin
4.15.5 Development Strategy
4.16 DaShenLin Pharmaceutical Group Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.16.3 Revenue Structure
4.16.4 Gross Margin
4.16.5 Development Strategy
4.17 Yunnan Jianzhijia Health Chain Co., Ltd.
4.17.1 Profile
4.17.2 Operation
4.17.3 Revenue Structure
4.17.4 Gross Margin
4.17.5 Development Strategy
4.18 Yifeng Pharmacy Chain Co., Ltd.
4.18.1 Profile
4.18.2 Operation
4.18.3 Revenue Structure
4.18.4 Gross Margin
4.18.5 Development Strategy
4.19 Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd.
4.19.1 Profile
4.19.2 Operation
4.19.3 Revenue Structure
4.19.4 Gross Margin
4.19.5 Development Strategy
4.20 LBX Pharmacy Chain co., Ltd
4.20.1 Profile
4.20.2 Operation
4.20.3 Revenue Structure
4.20.4 Gross Margin
4.20.5 Development Strategy
China Pharmaceutical Distribution Channel
Difference between Pure Marketing and Allocation in China’s Pharmaceutical Distribution
China’s Laws and Regulations on Pharmaceutical Distribution Industry, 2001-2018
China’s GDP, 2012-2018
Number of Medical and Healthcare Institutions in China, 2015-2018
Number of Hospitals in China, 2009-2018
Number of Hospitals in China by Economic Type, 2009-2018
Health Expenditure in China, 2010-2018
Health Expenditure in China, 2016-2025E
Population Aged over 65 in China, 2015-2025E
Residents’ Per-capita Disposable Income and YoY Growth in China, 2011-2018
Business Models of China Pharmaceutical Distribution Industry by Market
Comparison of Specialty, Economic Effect and Convenience between Three Drug End Markets in China
Total Number of Licensed Pharmacists in China, 2013-2018
Pharmaceutical Distribution Market Size and YoY Growth in China, 2006-2018
Pharmaceutical Distribution Market Size and YoY Growth in China, 2016-2025E
Pharmaceutical Distribution Sales Structure in China by Type, 2017
Pharmaceutical Distribution Sales Structure in China by Region, 2017
Pharmaceutical Distribution Revenue in China by Region, 2017
TOP20 Pharmaceutical Distribution Enterprises in China by Operating Revenue, 2017
China’s Policies on Online Medical Care, 2018
Capital Layout in China’s Drug Retailing in Recent Years
Regional Distribution of Drugstores Invested by Primary/Secondary Capital in China
Medicine Regulation Policies Make Drug Retail Stores Market More Concentrated in China, 2015-2019
Representative Pharmaceutical Distribution Enterprises in China by Regional Market
China’s Policies about Outflow of Prescriptions, 2015-2018
Development History of Drugstore Chain Industry in China
Drug Retail Market Size and YoY Growth in China, 2012-2018
Drug Retail Market Size and YoY Growth in China, 2016-2025E
Average Gross Margin of Demonstration Companies on China’s Drugstore Value List, 2010-2018
Average Net Margin of Demonstration Companies on China’s Drugstore Value List, 2010-2018
Number of Drug Retail Chains in China, 2012-2018
Drug Retail Chains in China by Number of Stores, 2012-2018
Number of Independent Retail Drugstores in China, 2012-2018
Share of Drugstore Chains in China, 2009-2018
Share of Drugstore Chains by Administration Area in China, 2018
TOP100 Pharmacy Chains in China by Total Revenue, 2017
TOP100 Pharmacy Chains in China by Number of Pharmacies, 2018
TOP20 Online Pharmacies in China by Revenue, 2016
TOP100 Independent Pharmacies in China by Revenue, 2018
Share of New Drugstores in China, 2014-2018
Companies with New Drugstores Accounting for over 30% of Their Total Number of Stores in China, 2018
Average Investment of Single Drugstores in China, 2014-2018 
Share of Drugstores Shut down in China, 2014-2018
Companies with Drugstores Shut down Accounting for over 5% of Their Total Number of Stores in China, 2018
Share of Medical Insurance Designated Drugstores in China, 2014-2018
Companies with More Than 600 Medical Insurance Designated Drugstores in China, 2018
Companies with Medical Insurance Designated Drugstores Accounting for over 95% of Their Total Number of Stores in China, 2018
Per Customer Transaction of Drugstores in China, 2013-2018
Companies with Per Customer Transaction of Their Drugstores Exceeding RMB135, 2018
Comparison of Revenue between Main Drug Retailers in China, 2013-2018
Comparison of Net Income between Main Drug Retailers in China, 2013-2018
Comparison of Gross Margin between Main Drug Retailers in China, 2013-2018
Revenue and Net Income of China National Accord Medicines, 2013-2018
Revenue Breakdown of China National Accord Medicines by Business, 2015-2018
Revenue Breakdown of China National Accord Medicines by Region, 2015-2018
China National Accord Medicines’ Revenue from Top 5 Clients, 2014-2018
Revenue and Net Income of Nanjing Pharmaceutical, 2013-2018
Revenue Breakdown of Nanjing Pharmaceutical by Business, 2015-2018
Revenue Breakdown of Nanjing Pharmaceutical by Region, 2014-2018
Revenue Structure of Nanjing Pharmaceutical by Region, 2014-2018
Gross Margin of Nanjing Pharmaceutical by Business, 2014-2018
Revenue and Net Income of Shanghai No.1 Pharmacy, 2013-2018
Revenue Breakdown of Shanghai No.1 Pharmacy by Business, 2014-2018
Revenue Structure of Shanghai No.1 Pharmacy by Business, 2014-2018
Gross Margin of Shanghai No.1 Pharmacy, 2014-2018
Gross Margin of Shanghai No.1 Pharmacy by Business, 2014-2018
Revenue and Net Income of China National Medicines, 2013-2018
Revenue Breakdown of China National Medicines by Business, 2014-2018
Revenue Structure of China National Medicines by Business, 2014-2018
Revenue Breakdown of China National Medicines by Region, 2014-2018
Revenue Structure of China National Medicines by Region, 2014-2018
Gross Margin of China National Medicines, 2014-2018
Gross Margin of China National Medicines by Business, 2014-2018
Revenue and Net Income of Huadong Medicine, 2013-2018
Revenue Breakdown of Huadong Medicine by Sector, 2014-2018
Revenue Structure of Huadong Medicine by Sector, 2014-2018
Gross Margin of Huadong Medicine by Sector, 2014-2018
Huadong Medicine’s Revenue from Top5 Clients and % of Total Revenue, 2014-2018
Revenue and Net Income of Cachet Pharmaceutical, 2013-2018
Revenue Breakdown of Cachet Pharmaceutical by Business, 2014-2018
Revenue Structure of Cachet Pharmaceutical by Business, 2014-2018
Revenue Breakdown of Cachet Pharmaceutical by Region, 2014-2018
Revenue Structure of Cachet Pharmaceutical by Region, 2014-2018
Gross Margin of Cachet Pharmaceutical’s Pharmaceutical Wholesale Business, 2014-2018
Cachet Pharmaceutical’s Revenue from Top5 Clients and % of Total Revenue, 2014-2018
Cachet Pharmaceutical’s Investment Projects with Raised Funds, 2016
Revenue and Net Income of Jointown Pharmaceutical Group, 2013-2018
Revenue Breakdown of Jointown Pharmaceutical Group by Business, 2014-2018
Revenue Structure of Jointown Pharmaceutical Group by Business, 2014-2018
Gross Margin of Jointown Pharmaceutical Group by Business, 2014-2018
Jointown Pharmaceutical Group’s Revenue from Top5 Clients and % of Total Revenue, 2014-2018
Revenue and Net Income of Realcan Pharmaceutical, 2013-2018
Revenue Breakdown of Realcan Pharmaceutical by Business, 2014-2018
Revenue Structure of Realcan Pharmaceutical by Business, 2014-2018
Gross Margin of Realcan Pharmaceutical by Business, 2014-2018
Revenue and Net Income of Shanghai Pharmaceuticals Holding, 2013-2018
Revenue Breakdown of Shanghai Pharmaceuticals Holding by Business, 2014-2018
Revenue Structure of Shanghai Pharmaceuticals Holding by Business, 2014-2018
Revenue Breakdown of Shanghai Pharmaceuticals Holding by Region, 2014-2018
Revenue Structure of Shanghai Pharmaceuticals Holding by Region, 2014-2018
Gross Margin of Shanghai Pharmaceuticals Holding by Business, 2014-2018
Revenue and Net Income of Zhejiang Int'l Group, 2013-2018
Revenue Breakdown of Zhejiang Int'l Group by Business, 2014-2018
Gross Margin of Zhejiang Int'l Group’s Pharmaceutical Sales Business, 2014-2018
Revenue and Net Income of Zhejiang Zhenyuan, 2013-2018
Revenue Breakdown of Zhejiang Zhenyuan by Business, 2014-2018
Revenue Structure of Zhejiang Zhenyuan by Business, 2014-2018
Gross Margin of Zhejiang Zhenyuan by Business, 2014-2018
Revenue and Net Income of China Meheco, 2013-2018
Revenue Breakdown of China Meheco by Business, 2014-2018
Revenue Structure of China Meheco by Business, 2014-2018
Gross Margin of China Meheco by Business, 2014-2018
Revenue and Net Income of Charmacy Pharmaceutical, 2013-2018
Revenue Breakdown of Charmacy Pharmaceutical by Product/Client, 2013-2018
Revenue Structure of Charmacy Pharmaceutical by Product/Client, 2013-2018
Gross Margin of Charmacy Pharmaceutical, 2013-2018
Charmacy Pharmaceutical’s Distribution Network in Guangdong as of June 2017
Luyan Pharma’s Investment Projects with Raised Funds by Initial Public Offerings
Revenue and Net Income of Luyan Pharma, 2013-2018
Revenue Breakdown of Luyan Pharma by Business, 2014-2018
Revenue Structure of Luyan Pharma by Business, 2014-2018
Gross Margin of Luyan Pharma’s Pharmaceutical Wholesale Business, 2014-2018
Revenue and Net Income of China Resources Pharmaceutical Group, 2013-2018
Revenue Breakdown of China Resources Pharmaceutical Group by Business, 2013-2018
Revenue Structure of China Resources Pharmaceutical Group by Business, 2013-2018
Gross Margin of China Resources Pharmaceutical Group, 2013-2018
Distribution Network Layout of China Resources Pharmaceutical Group
Revenue and Net Income of DaShenLin Pharmaceutical, 2013-2018
Revenue Breakdown of DaShenLin Pharmaceutical by Business, 2013-2018
Revenue Structure of DaShenLin Pharmaceutical by Business, 2013-2018
Gross Margin of DaShenLin Pharmaceutical, 2013-2018
Revenue and Net Income of Yunnan Jianzhijia, 2013-2018
Revenue Breakdown of Yunnan Jianzhijia by Business, 2013-2018
Revenue Structure of Yunnan Jianzhijia by Business, 2013-2018
Gross Margin of Yunnan Jianzhijia, 2013-2018
Revenue and Net Income of Yifeng Pharmacy, 2013-2018
Revenue Breakdown of Yifeng Pharmacy by Business, 2013-2018
Revenue Structure of Yifeng Pharmacy by Business, 2013-2018
Gross Margin of Yifeng Pharmacy, 2013-2018
Yifeng Pharmacy’s M&A Cases for Extensive Growth, 2011-2018
Revenue and Net Income of Yixintang Pharmaceutical, 2013-2018
Revenue Breakdown of Yixintang Pharmaceutical by Business, 2013-2018
Revenue Structure of Yixintang Pharmaceutical by Business, 2013-2018
Gross Margin of Yixintang Pharmaceutical, 2013-2018
Yixintang Pharmaceutical’s M&A Cases for Extensive Growth, 2014-2018
Revenue and Net Income of LBX Pharmacy, 2013-2018
Revenue Breakdown of LBX Pharmacy by Business, 2013-2018
Revenue Structure of LBX Pharmacy by Business, 2013-2018
Gross Margin of LBX Pharmacy, 2013-2018

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号